Albumin/Creatinine Ratio: When Is Treatment Discussed?

What this test measures

The UACR divides the concentration of albumin in a urine sample by the concentration of creatinine in the same sample. This correction for urine dilution is why a single spot sample can substitute for a 24-hour urine collection in most outpatient situations, avoiding the burden of a timed collection. The result is reported in mg/g (US convention) or mg/mmol (SI convention).

A healthy glomerular filtration barrier allows very little albumin to pass into urine. When the barrier is damaged, whether from diabetes, hypertension, glomerulonephritis, or other causes, albumin leaks through in measurable amounts. The UACR is therefore used both as a kidney-damage marker and, independently, as a marker of systemic vascular risk.

The core answer, with its boundary: in adults with diabetes or hypertension, a confirmed UACR at or above 30 mg/g is classified by KDIGO as at least moderately increased albuminuria and is associated with higher risk of kidney function decline and cardiovascular events; a single unconfirmed result does not establish this diagnosis, because transient elevations from infection, exercise, fever, or poor glycemic control are common and guideline groups require repeat testing before treatment decisions are anchored to the number.

Who guidelines say should be tested, and how often

The ADA's Standards of Care has recommended, in recent editions, that both a UACR and an estimated GFR be checked at least annually in people with diabetes, generally starting at diagnosis for type 2 diabetes and after several years of disease duration for type 1 diabetes. Exact wording and the specific evidence grade change between annual editions, so the current edition should be checked directly rather than relied on secondhand.

Beyond diabetes, UACR testing is commonly ordered, based on guideline and observational literature, in:

• Hypertension, especially when clinicians are assessing for target-organ damage
• Chronic kidney disease staging and monitoring (paired with eGFR)
• Pregnancy when preeclampsia is suspected
• Heart failure evaluation, where albuminuria has been studied as a prognostic marker independent of ejection fraction
• Patients starting an SGLT2 inhibitor or other kidney-protective therapy, to establish a baseline
• Systemic lupus erythematosus with suspected renal involvement

A real-world consideration for hypertension care is that albuminuria screening is frequently under-ordered even when guidelines call for it. A recent evaluation of electronic health record clinical decision support changes found that redesigning screening prompts measurably improved albuminuria screening rates among patients with hypertension, which suggests that ordering gaps are as much a systems problem as a clinical judgment problem (Pottel et al., 2026). This is observational, health-system-level evidence about screening behavior, not a claim about the test's diagnostic performance.

Normal, moderately increased, and severely increased ranges

KDIGO's staging framework, first introduced in 2012 and used in subsequent updates, classifies albuminuria into three tiers:

• A1 (normal to mildly increased): below 30 mg/g. No albuminuria-specific therapy is indicated based on this value alone; general cardiovascular risk management still applies.
• A2 (moderately increased): 30 to 300 mg/g. This range is where guideline bodies recommend confirmation and consideration of RAAS-blocking therapy (ACE inhibitors or ARBs) if not already in use.
• A3 (severely increased): above 300 mg/g. This range is associated in guideline literature with more advanced glomerular injury and typically prompts nephrology referral, particularly when eGFR is also reduced.

Some laboratories use a lower threshold for men to account for higher average creatinine excretion, but this sex-specific cutoff is not part of KDIGO's core recommendation and practice varies by lab. If a report uses a locally adjusted cutoff, that should be stated on the lab report itself.

How to interpret one elevated result

A single elevated UACR is not diagnostic of chronic kidney disease. Recognized causes of a transient rise include urinary tract infection, vigorous exercise in the prior 24 hours, acute febrile illness, menstrual contamination of the sample, and poorly controlled hyperglycemia at the time of testing.

Because of this, guideline frameworks call for confirming an elevated result with repeat testing, generally on the order of two positive results out of three samples collected over several months, before treating the elevation as persistent albuminuria. Once confirmed, the UACR is paired with eGFR to place the patient into a combined risk category that guides referral and treatment intensity. A patient with a reduced eGFR and a confirmed UACR in the moderately or severely increased range falls into a higher combined-risk tier than either value would suggest alone.

Emerging research is also looking beyond the single UACR number. A 2026 study examining urinary extracellular vesicle proteomic signatures reported distinct molecular patterns associated with albuminuria and treatment response in diabetic kidney disease (2026). This is exploratory biomarker research, not a validated clinical test, and it should not be read as an alternative to UACR testing today.

Decision framework: should you order a UACR, and what should the result change?

This framework organizes the recurring decision points around UACR testing into a single reference. It reflects guideline patterns described above; it is not a substitute for a specific patient's clinical judgment.

The link between albuminuria and cardiovascular risk

Albuminuria is treated in the literature as a marker of systemic vascular and endothelial dysfunction, not only a kidney-specific finding. Large population cohort studies and hypertension guideline updates have incorporated UACR as a target-organ-damage marker that can shift a patient's overall cardiovascular risk classification. The exact magnitude of risk associated with a given UACR level varies across studies and populations, and readers should treat any single percentage figure (for example, a stated increase in cardiovascular mortality per doubling of UACR) as something to verify against the specific primary study rather than as a fixed universal number.

What lowering an elevated UACR involves

Several drug classes have been studied specifically for their effect on albuminuria, generally in the setting of diabetic kidney disease or broader chronic kidney disease trials:

• ACE inhibitors and ARBs (RAAS blockade) are the longest-established intervention and are recommended by guideline bodies as first-line therapy when albuminuria is confirmed in the moderately or severely increased range, particularly in diabetes.
• SGLT2 inhibitors have shown albuminuria-lowering effects in large kidney-outcome trials, independent of glucose-lowering effect, and current KDIGO guidance supports their use in a substantial subset of patients with albuminuria and reduced eGFR.
• Finerenone, a nonsteroidal mineralocorticoid receptor antagonist, is FDA-approved for reducing the risk of kidney disease progression in adults with chronic kidney disease associated with type 2 diabetes; it has also been studied for its effect on albuminuria specifically.
• GLP-1 receptor agonists have kidney outcome data in type 2 diabetes, including effects on markers of kidney disease progression, though the details of which populations benefit and by how much should be confirmed against the specific trial before being applied to an individual patient.

Exact percentage reductions attributed to any of these drugs in specific trials (for example, particular numbers cited for RENAAL, IDNT, DAPA-CKD, or FIDELIO-DKD) are widely quoted online but should be verified against the primary trial publication before being used in patient counseling, because secondary summaries frequently round or misstate these figures.

Non-drug measures with support in guideline literature include blood pressure control to guideline-recommended targets, glycemic optimization in diabetes, sodium restriction, and smoking cessation. Weight loss has also been associated with reduced albuminuria in some studies, plausibly through reduced glomerular hyperfiltration, though this is an area where more evidence is being generated.

One additional and easily overlooked factor is that everyday substances can shift UACR independent of kidney disease progression. A UK cohort and Mendelian randomization study examining glucosamine, a common over-the-counter joint supplement, found an association with albuminuria (2025). This is observational and genetic-instrument evidence, not proof of a dose-dependent clinical effect in every patient, but it is a reasonable reason to ask about supplement use, along with NSAID use, when a UACR result is unexpectedly abnormal or unexpectedly improved.

What a low UACR means, and what it does not mean

A UACR below 30 mg/g is the expected, reassuring result. There is no recognized clinical concern associated with a UACR that is "too low." Albumin is produced by the liver and is filtered minimally by a healthy glomerulus, so a very low urine albumin level does not indicate a protein deficiency or nutritional problem.

The one situation worth double-checking is a sudden, large drop from a previously elevated value (for example, from the severely increased range down to normal) without any documented treatment change. This pattern is more likely to reflect a dilute sample or a lab handling issue than a true resolution of kidney disease, and repeating the test with a first-morning void is a reasonable next step.

Specimen collection basics

A first-morning void is preferred because it reduces variability associated with daytime activity and orthostatic effects on protein excretion. General instructions used in practice include avoiding vigorous exercise in the 24 hours before collection, collecting a clean midstream sample, and noting any current fever, urinary symptoms, or menstruation on the requisition, since these can confound the result. No fasting is required.

When hematuria is also present on a concurrent dipstick urinalysis, that combination raises the possibility of glomerulonephritis rather than isolated diabetic or hypertensive kidney disease, and it typically prompts a different workup, including complement levels and relevant autoantibody testing, rather than reassurance based on the UACR alone.

Special populations, briefly

• Pregnancy: Albuminuria in the range guideline bodies associate with preeclampsia, combined with new-onset hypertension after 20 weeks, is a criterion obstetric providers use in preeclampsia evaluation. Obstetric protocols, not this general framework, should govern management.
• Heart failure: Albuminuria has been studied as a prognostic marker in heart failure populations regardless of ejection fraction category, though it is used as risk stratification rather than as a treatment target in most cardiology practice today.
• Obesity without diabetes: Obesity-related glomerulopathy is a recognized entity, and some guideline language supports UACR screening in patients with obesity plus additional metabolic risk factors even without a diabetes diagnosis.
• Pediatric populations: Pediatric diabetes guideline bodies have recommended UACR screening beginning at a defined age or duration of disease; because pediatric screening schedules change between guideline editions, the current pediatric-specific guideline should be checked directly rather than assumed.

Medications and substances that can shift the result

• NSAIDs can acutely and artificially lower measured albuminuria through their effect on kidney blood flow, which can mask underlying glomerular injury.
• ACE inhibitors, ARBs, SGLT2 inhibitors, and finerenone are each associated with reductions in UACR as part of their intended kidney-protective effect.
• Calcineurin inhibitors (tacrolimus, cyclosporine) have been associated with increased albuminuria through direct kidney effects.
• Glucosamine supplement use has an observational association with albuminuria, as noted above, and is worth asking about when interpreting an unexplained result.

A rising UACR in a patient on stable, unchanged therapy deserves more concern than a rising UACR that coincides with starting or stopping one of these agents.

Cost and ordering logistics

UACR testing is broadly covered by Medicare, Medicaid, and most commercial insurers when ordered with an appropriate diagnosis code, though coverage specifics vary by plan and should be confirmed with the patient's insurer. Self-pay pricing varies by lab and geography; a commonly cited approximate range is $15 to $45, but exact current pricing should be confirmed directly with the ordering lab rather than assumed from older published figures. The test uses a standard urine specimen cup, and most laboratories offer a single combined order for urine albumin and urine creatinine. Results are typically available within a day or two at major reference labs, though turnaround varies by lab and by whether send-out testing is required.

At-home and point-of-care UACR testing options exist and have been evaluated against standard laboratory testing in validation studies; agreement has generally been reported as good but not perfect, and clinicians should treat at-home results as a monitoring tool that may still need laboratory confirmation for major treatment decisions.

What is established, what is plausible, and what is not established

Established: Guideline bodies including the ADA and KDIGO recommend UACR testing for defined populations, most clearly people with diabetes and people with hypertension or other chronic kidney disease risk factors. A confirmed result in the moderately or severely increased range is associated with higher risk of kidney disease progression and has informed treatment decisions such as starting RAAS blockade or an SGLT2 inhibitor.

Plausible but requiring case-by-case verification: Specific percentage effect sizes attributed to individual drugs or trials, specific cardiovascular risk multipliers per doubling of UACR, and specific cost figures. These numbers appear frequently in secondary sources but should be checked against the primary trial or guideline document before being used to counsel a specific patient.

Not established as a matter of general practice: Extending screening intervals beyond guideline-recommended annual testing in diabetes, even in patients with a long history of normal results, is not endorsed by major guideline bodies as a formal, evidence-supported practice, even though some clinicians apply risk-stratified judgment in low-risk patients.

Common questions

References

• Pottel H, et al. Improvements in Albuminuria Screening Among Individuals with Hypertension Associated with Electronic Health Record Clinical Decision Support Design Changes. 2026. https://pubmed.ncbi.nlm.nih.gov/41728306/
• Distinct proteomic signatures of urinary extracellular vesicles link to albuminuria and treatment responses in diabetic kidney disease. 2026. https://pubmed.ncbi.nlm.nih.gov/42173279/
• Association between glucosamine use and albuminuria in the UK: a cohort and Mendelian randomisation study. 2025. https://pubmed.ncbi.nlm.nih.gov/41271412/

Guideline statements attributed to the ADA Standards of Care, KDIGO, ESC/ESH, ACOG, and AACE in this article should be verified against the current published edition of each guideline before being used for clinical decision-making, since specific numeric thresholds and recommendation wording are updated periodically and the exact source documents were not independently confirmed for this draft.